SG11202111056YA - Methods for treatment of subjects with psoriatic arthritis - Google Patents

Methods for treatment of subjects with psoriatic arthritis

Info

Publication number
SG11202111056YA
SG11202111056YA SG11202111056YA SG11202111056YA SG11202111056YA SG 11202111056Y A SG11202111056Y A SG 11202111056YA SG 11202111056Y A SG11202111056Y A SG 11202111056YA SG 11202111056Y A SG11202111056Y A SG 11202111056YA SG 11202111056Y A SG11202111056Y A SG 11202111056YA
Authority
SG
Singapore
Prior art keywords
antibody
week
dose
patient
seq
Prior art date
Application number
SG11202111056YA
Other languages
English (en)
Inventor
Kirti Wardhaman Ganorkar
Atul Mathuradas Raut
Anil Raghavan
Siu-Long Yao
Original Assignee
Sun Pharmaceutical Ind Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=72837755&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG11202111056Y(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sun Pharmaceutical Ind Ltd filed Critical Sun Pharmaceutical Ind Ltd
Publication of SG11202111056YA publication Critical patent/SG11202111056YA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
SG11202111056YA 2019-04-15 2020-04-15 Methods for treatment of subjects with psoriatic arthritis SG11202111056YA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN201921015050 2019-04-15
IN202021004422 2020-01-31
PCT/IB2020/053565 WO2020212874A1 (en) 2019-04-15 2020-04-15 Methods for treatment of subjects with psoriatic arthritis

Publications (1)

Publication Number Publication Date
SG11202111056YA true SG11202111056YA (en) 2021-11-29

Family

ID=72837755

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202111056YA SG11202111056YA (en) 2019-04-15 2020-04-15 Methods for treatment of subjects with psoriatic arthritis

Country Status (16)

Country Link
US (1) US20220298233A1 (https=)
EP (1) EP3956357A4 (https=)
JP (2) JP7628962B2 (https=)
KR (1) KR20210140780A (https=)
CN (1) CN113825768A (https=)
AU (1) AU2020259375A1 (https=)
BR (1) BR112021020612A2 (https=)
CA (1) CA3143604A1 (https=)
IL (1) IL287213A (https=)
JO (1) JOP20210279A1 (https=)
MA (1) MA55729A (https=)
MX (1) MX2021012652A (https=)
MY (1) MY210310A (https=)
PH (1) PH12021552536A1 (https=)
SG (1) SG11202111056YA (https=)
WO (1) WO2020212874A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2024323792A1 (en) * 2023-08-11 2026-03-12 Innovent Biologics (Suzhou) Co., Ltd. Method for treating plaque psoriasis wherein subject previously receiving biologic therapy for plaque psoriasis switches to using anti-il23p19 antibody
AU2024338774A1 (en) * 2023-09-07 2026-03-26 Innovent Biologics (Suzhou) Co., Ltd. Method for treating moderate and severe psoriasis using recombinant anti-il-23p19 antibody
WO2026069253A1 (en) * 2024-09-30 2026-04-02 Sun Pharmaceutical Industries Limited Long term safety of tildrakizumab in psoriatic arthritis

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7807389B2 (en) * 2003-03-14 2010-10-05 University Of Rochester Methods and compositions related to joint inflammation diseases
EP2007426A4 (en) * 2006-04-10 2010-06-16 Abbott Biotech Ltd COMPOSITIONS FOR THE TREATMENT OF PSORIASTIC POLYARTHRITIS AND THEIR APPLICATIONS
AR065420A1 (es) * 2007-02-23 2009-06-03 Schering Corp Anticuerpos anti-il-23 p19 de ingenieria
CA2734919C (en) * 2008-08-27 2016-08-16 Schering Corporation Lyophilized formulations of engineered anti-il-23p19 antibodies
PE20141162A1 (es) * 2010-11-04 2014-09-18 Boehringer Ingelheim Int Anticuerpos anti-il-23
ES2729603T3 (es) * 2012-06-27 2019-11-05 Merck Sharp & Dohme Anticuerpos IL-23 antihumanos cristalinos
UA117466C2 (uk) * 2012-12-13 2018-08-10 Мерк Шарп Енд Доме Корп. СТАБІЛЬНИЙ СКЛАД У ВИГЛЯДІ РОЗЧИНУ АНТИТІЛА ДО IL-23p19

Also Published As

Publication number Publication date
MY210310A (en) 2025-09-10
JP2022529266A (ja) 2022-06-20
US20220298233A1 (en) 2022-09-22
AU2020259375A1 (en) 2021-10-28
EP3956357A1 (en) 2022-02-23
BR112021020612A2 (pt) 2021-12-28
JP2025069284A (ja) 2025-04-30
KR20210140780A (ko) 2021-11-23
PH12021552536A1 (en) 2022-07-04
CN113825768A (zh) 2021-12-21
MA55729A (fr) 2022-02-23
JP7628962B2 (ja) 2025-02-12
JOP20210279A1 (ar) 2021-10-14
EP3956357A4 (en) 2023-01-04
WO2020212874A1 (en) 2020-10-22
IL287213A (en) 2021-12-01
CA3143604A1 (en) 2020-10-22
MX2021012652A (es) 2022-01-24

Similar Documents

Publication Publication Date Title
US20240376210A1 (en) Vedolizumab for the treatment of fistulizing crohn's disease
JP2025069284A (ja) 乾癬性関節炎に罹患している対象者の治療方法
RU2697383C2 (ru) Применение антагонистов il-17 для торможения прогрессирования структурных повреждений у пациентов с псориатическим артритом
RU2723047C2 (ru) Средство для лечения множественной миеломы (ММ)
US20240059783A1 (en) Anti-ox40 antagonistic antibodies and dosage for the treatment of ox40-mediated disorders
CN112689512B (zh) 用于治疗银屑病的组合物和方法
CN119095617A (zh) 用于治疗患有头皮斑块型银屑病的受试者的方法
US20220177568A1 (en) Treatment of skin lesions and pruritus in prurigo nodularis patients
JP2025508766A (ja) Ｆｃｒｎアンタゴニストを使用して筋炎を治療するための方法
JP2026062653A (ja) シェーグレン症候群の処置
TWI870471B (zh) 全身性硬化症治療用醫藥組合物
EP4623002A2 (en) Methods for the treatment of thyroid eye disease
EP3749353B1 (en) Nemolizumab in the treatment of atopic dermatitis with moderate to severe excoriation
RU2852738C1 (ru) Способы лечения аутоиммунных заболеваний с применением антагонистов интерлейкина-17 (il-17)
CN118846041A (zh) 用于治疗化脓性汗腺炎的pan-elr+cxc趋化因子抗体
EP3952993B1 (en) Method of treating fumaric acid ester-resistant plaque psoriasis
TW202535943A (zh) 改善抗ＦｃＲｎ療法之方法
WO2025146509A1 (en) Methods of treating multifocal motor neuropathy (mmn)
CN121079321A (zh) 治疗溃疡性结肠炎的方法
CN117120092A (zh) 用于治疗儿科重症肌无力的组合物和方法
HK40117117A (zh) 用於治疗多灶性运动神经病(mmn)的给药方案